Outcome of prosthetic joint infections treated with debridement and retention of components

C. E. Marculescu, E. F. Berbari, A. D. Hanssen, J. M. Steckelberg, S. W. Harmsen, Jayawant Mandrekar, Douglas R. Osmon

Research output: Contribution to journalArticle

312 Citations (Scopus)

Abstract

Background. Debridement and retention of the prosthesis represents an attractive surgical modality for treatment of prosthetic joint infection, but risk factors for treatment failure require clarification. Methods. We conducted a retrospective cohort analysis of all patients with a prosthetic joint infection who were treated with debridement and retention of the prosthesis at the Mayo Clinic (Rochester, Minnesota) between 1995 and 1999. Results. Debridement and retention of the prosthesis was the initial treatment modality for 99 episodes of prosthetic joint infection that occurred in 91 patients who presented to the Mayo Clinic during 1995-1999. A total of 32% and 23% of all episodes were due to Staphylococcus aureus and coagulase-negative staphylococci, respectively. The median duration of intravenous antimicrobial therapy was 28 days (range, 1-90 days). Oral antimicrobial suppression was used in 89% of the episodes, for a median duration of 541 days (range, 5-2673 days). Treatment failure occurred in 53 episodes during a median follow-up period of 700 days (range, 1-2779 days). The 2-year survival rate free of treatment failure was 60% (95% confidence interval [CI], 50%-71%). Variables associated with an increased risk of treatment failure in multivariable analysis included the presence of a sinus tract (hazard ratio, 2.84; 95% CI, 1.48-5.44; P = .002) and a duration of symptoms prior to debridement of ≥8 days (hazard ratio, 1.77; 95% CI, 1.02-3.07; P = .04). Conclusions. Debridement and retention of the prosthesis is a common surgical modality at our institution to treat prosthetic joint infection. Risk factors independently associated with treatment failure include the presence of a sinus tract and duration of symptoms prior to debridement of ≥8 days.

Original languageEnglish (US)
Pages (from-to)471-478
Number of pages8
JournalClinical Infectious Diseases
Volume42
Issue number4
DOIs
StatePublished - Feb 15 2006

Fingerprint

Debridement
Prosthesis Retention
Treatment Failure
Joints
Infection
Confidence Intervals
Coagulase
Staphylococcus
Staphylococcus aureus
Cohort Studies
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Immunology

Cite this

Marculescu, C. E., Berbari, E. F., Hanssen, A. D., Steckelberg, J. M., Harmsen, S. W., Mandrekar, J., & Osmon, D. R. (2006). Outcome of prosthetic joint infections treated with debridement and retention of components. Clinical Infectious Diseases, 42(4), 471-478. https://doi.org/10.1086/499234

Outcome of prosthetic joint infections treated with debridement and retention of components. / Marculescu, C. E.; Berbari, E. F.; Hanssen, A. D.; Steckelberg, J. M.; Harmsen, S. W.; Mandrekar, Jayawant; Osmon, Douglas R.

In: Clinical Infectious Diseases, Vol. 42, No. 4, 15.02.2006, p. 471-478.

Research output: Contribution to journalArticle

Marculescu, CE, Berbari, EF, Hanssen, AD, Steckelberg, JM, Harmsen, SW, Mandrekar, J & Osmon, DR 2006, 'Outcome of prosthetic joint infections treated with debridement and retention of components', Clinical Infectious Diseases, vol. 42, no. 4, pp. 471-478. https://doi.org/10.1086/499234
Marculescu, C. E. ; Berbari, E. F. ; Hanssen, A. D. ; Steckelberg, J. M. ; Harmsen, S. W. ; Mandrekar, Jayawant ; Osmon, Douglas R. / Outcome of prosthetic joint infections treated with debridement and retention of components. In: Clinical Infectious Diseases. 2006 ; Vol. 42, No. 4. pp. 471-478.
@article{95cf48486b45409ba3d68646d7ed963e,
title = "Outcome of prosthetic joint infections treated with debridement and retention of components",
abstract = "Background. Debridement and retention of the prosthesis represents an attractive surgical modality for treatment of prosthetic joint infection, but risk factors for treatment failure require clarification. Methods. We conducted a retrospective cohort analysis of all patients with a prosthetic joint infection who were treated with debridement and retention of the prosthesis at the Mayo Clinic (Rochester, Minnesota) between 1995 and 1999. Results. Debridement and retention of the prosthesis was the initial treatment modality for 99 episodes of prosthetic joint infection that occurred in 91 patients who presented to the Mayo Clinic during 1995-1999. A total of 32{\%} and 23{\%} of all episodes were due to Staphylococcus aureus and coagulase-negative staphylococci, respectively. The median duration of intravenous antimicrobial therapy was 28 days (range, 1-90 days). Oral antimicrobial suppression was used in 89{\%} of the episodes, for a median duration of 541 days (range, 5-2673 days). Treatment failure occurred in 53 episodes during a median follow-up period of 700 days (range, 1-2779 days). The 2-year survival rate free of treatment failure was 60{\%} (95{\%} confidence interval [CI], 50{\%}-71{\%}). Variables associated with an increased risk of treatment failure in multivariable analysis included the presence of a sinus tract (hazard ratio, 2.84; 95{\%} CI, 1.48-5.44; P = .002) and a duration of symptoms prior to debridement of ≥8 days (hazard ratio, 1.77; 95{\%} CI, 1.02-3.07; P = .04). Conclusions. Debridement and retention of the prosthesis is a common surgical modality at our institution to treat prosthetic joint infection. Risk factors independently associated with treatment failure include the presence of a sinus tract and duration of symptoms prior to debridement of ≥8 days.",
author = "Marculescu, {C. E.} and Berbari, {E. F.} and Hanssen, {A. D.} and Steckelberg, {J. M.} and Harmsen, {S. W.} and Jayawant Mandrekar and Osmon, {Douglas R.}",
year = "2006",
month = "2",
day = "15",
doi = "10.1086/499234",
language = "English (US)",
volume = "42",
pages = "471--478",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Outcome of prosthetic joint infections treated with debridement and retention of components

AU - Marculescu, C. E.

AU - Berbari, E. F.

AU - Hanssen, A. D.

AU - Steckelberg, J. M.

AU - Harmsen, S. W.

AU - Mandrekar, Jayawant

AU - Osmon, Douglas R.

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Background. Debridement and retention of the prosthesis represents an attractive surgical modality for treatment of prosthetic joint infection, but risk factors for treatment failure require clarification. Methods. We conducted a retrospective cohort analysis of all patients with a prosthetic joint infection who were treated with debridement and retention of the prosthesis at the Mayo Clinic (Rochester, Minnesota) between 1995 and 1999. Results. Debridement and retention of the prosthesis was the initial treatment modality for 99 episodes of prosthetic joint infection that occurred in 91 patients who presented to the Mayo Clinic during 1995-1999. A total of 32% and 23% of all episodes were due to Staphylococcus aureus and coagulase-negative staphylococci, respectively. The median duration of intravenous antimicrobial therapy was 28 days (range, 1-90 days). Oral antimicrobial suppression was used in 89% of the episodes, for a median duration of 541 days (range, 5-2673 days). Treatment failure occurred in 53 episodes during a median follow-up period of 700 days (range, 1-2779 days). The 2-year survival rate free of treatment failure was 60% (95% confidence interval [CI], 50%-71%). Variables associated with an increased risk of treatment failure in multivariable analysis included the presence of a sinus tract (hazard ratio, 2.84; 95% CI, 1.48-5.44; P = .002) and a duration of symptoms prior to debridement of ≥8 days (hazard ratio, 1.77; 95% CI, 1.02-3.07; P = .04). Conclusions. Debridement and retention of the prosthesis is a common surgical modality at our institution to treat prosthetic joint infection. Risk factors independently associated with treatment failure include the presence of a sinus tract and duration of symptoms prior to debridement of ≥8 days.

AB - Background. Debridement and retention of the prosthesis represents an attractive surgical modality for treatment of prosthetic joint infection, but risk factors for treatment failure require clarification. Methods. We conducted a retrospective cohort analysis of all patients with a prosthetic joint infection who were treated with debridement and retention of the prosthesis at the Mayo Clinic (Rochester, Minnesota) between 1995 and 1999. Results. Debridement and retention of the prosthesis was the initial treatment modality for 99 episodes of prosthetic joint infection that occurred in 91 patients who presented to the Mayo Clinic during 1995-1999. A total of 32% and 23% of all episodes were due to Staphylococcus aureus and coagulase-negative staphylococci, respectively. The median duration of intravenous antimicrobial therapy was 28 days (range, 1-90 days). Oral antimicrobial suppression was used in 89% of the episodes, for a median duration of 541 days (range, 5-2673 days). Treatment failure occurred in 53 episodes during a median follow-up period of 700 days (range, 1-2779 days). The 2-year survival rate free of treatment failure was 60% (95% confidence interval [CI], 50%-71%). Variables associated with an increased risk of treatment failure in multivariable analysis included the presence of a sinus tract (hazard ratio, 2.84; 95% CI, 1.48-5.44; P = .002) and a duration of symptoms prior to debridement of ≥8 days (hazard ratio, 1.77; 95% CI, 1.02-3.07; P = .04). Conclusions. Debridement and retention of the prosthesis is a common surgical modality at our institution to treat prosthetic joint infection. Risk factors independently associated with treatment failure include the presence of a sinus tract and duration of symptoms prior to debridement of ≥8 days.

UR - http://www.scopus.com/inward/record.url?scp=32044443654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044443654&partnerID=8YFLogxK

U2 - 10.1086/499234

DO - 10.1086/499234

M3 - Article

C2 - 16421790

AN - SCOPUS:32044443654

VL - 42

SP - 471

EP - 478

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -